CIK 0001070081 · Large accelerated filer
PTC THERAPEUTICS, INC.
Sign in to watch- Ticker
- PTCT
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 043416587
- Phone
- 9082227000
- Business address
- 500 WARREN CORPORATE CENTER DRIVE, WARREN, NJ, 07059
- Former names
- PTC THERAPEUTICS INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $7,752,145
- in 10 filings, $7.8M under 10b5-1 plans
Net −$7,752,145. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-09-10 | SCHMERTZLER MICHAEL Director | Sale 10b5-1 | −10,000 | $67.34 | $673K | 1,316,594 |
| 2026-09-09 | SCHMERTZLER MICHAEL Director | Sale 10b5-1 | −9,428 | $67.79 | $639K | 1,327,166 |
| 2026-09-09 | SCHMERTZLER MICHAEL Director | Sale 10b5-1 | −572 | $68.67 | $39K | 1,326,594 |
| 2026-08-27 | SCHMERTZLER MICHAEL Director | Sale 10b5-1 | −11,890 | $71.55 | $851K | 1,337,204 |
| 2026-08-27 | SCHMERTZLER MICHAEL Director | Sale 10b5-1 | −610 | $72.22 | $44K | 1,336,594 |
| 2026-08-26 | SCHMERTZLER MICHAEL Director | Sale 10b5-1 | −6,874 | $72.74 | $500K | 1,354,720 |
| 2026-08-26 | SCHMERTZLER MICHAEL Director | Sale 10b5-1 | −5,626 | $73.18 | $412K | 1,349,094 |
| 2026-08-20 | SCHMERTZLER MICHAEL Director | Sale 10b5-1 | −9,419 | $70.78 | $667K | 1,364,675 |
| 2026-08-20 | SCHMERTZLER MICHAEL Director | Sale 10b5-1 | −2,390 | $71.88 | $172K | 1,362,285 |
| 2026-08-20 | SCHMERTZLER MICHAEL Director | Sale 10b5-1 | −691 | $72.92 | $50K | 1,361,594 |
| 2026-08-19 | SCHMERTZLER MICHAEL Director | Sale 10b5-1 | −5,335 | $72.86 | $389K | 1,381,259 |
| 2026-08-19 | SCHMERTZLER MICHAEL Director | Sale 10b5-1 | −7,165 | $73.67 | $528K | 1,374,094 |
| 2026-08-17 | Boulding Mark Elliott EXEC. VP AND CLO | Option exercise 10b5-1 | +2,813 | $25.69 | $72K | 108,085 |
| 2026-08-17 | Boulding Mark Elliott EXEC. VP AND CLO | Sale 10b5-1 | −1,844 | $72.39 | $133K | 106,241 |
| 2026-08-17 | Boulding Mark Elliott EXEC. VP AND CLO | Sale 10b5-1 | −969 | $72.90 | $71K | 105,272 |
| 2026-08-17 | Boulding Mark Elliott EXEC. VP AND CLO | Option exercise · Stock Option (Right to Buy) 10b5-1 | −2,813 | 16,876 | ||
| 2026-08-04 | Klein Matthew B. CHIEF EXECUTIVE OFFICER | Sale 10b5-1 | −10,292 | $68.57 | $706K | 383,868 |
| 2026-07-28 | Sollie-Zetlmayer Hege Elisabeth Director | Grant or award | +4,000 | 50,526 | ||
| 2026-07-28 | Sollie-Zetlmayer Hege Elisabeth Director | Grant or award | +2,000 | 52,526 | ||
| 2026-07-28 | Sollie-Zetlmayer Hege Elisabeth Director | Grant or award · Stock Option (Right to Buy) | +3,475 | 3,475 |
Page 2 of 25 · 493 trades